Altimmune, Inc. (ALT) — SEC Filings
Altimmune, Inc. (ALT) — 37 SEC filings. Latest: S-3MEF (Apr 23, 2026). Includes 12 8-K, 11 SC 13G/A, 6 10-Q.
View Altimmune, Inc. on SEC EDGAR
Overview
Altimmune, Inc. (ALT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-3MEF filed on Apr 23, 2026: Altimmune, Inc. filed an S-3MEF form on April 22, 2026, to register additional securities under a prior S-3 registration. This filing allows the company to potentially offer and sell more shares or other securities in the future, supplementing its existing registration statement.
Sentiment Summary
Across 37 filings, the sentiment breakdown is: 1 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Altimmune, Inc. is neutral.
Filing Type Overview
Altimmune, Inc. (ALT) has filed 1 S-3MEF, 12 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 11 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (37)
Risk Profile
Risk Assessment: Of ALT's 24 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $5 thousand |
| Net Income | -$19.014 million |
| EPS | -$0.21 |
| Debt-to-Equity | 0.18 |
| Cash Position | $61.278 million |
| Operating Margin | -100.0% |
| Total Assets | $218.447 million |
| Total Debt | $14.445 million |
Key Executives
- Dr. David J. Ebersole
- Mr. Scott M. Canute
- Dr. Vipin K. Garg
- Mr. Michael J. McVoy
- Dr. Scott Harris
- Vipin Garg
- Amy Comstock, MD
Industry Context
Altimmune operates in the highly competitive biopharmaceutical sector, focusing on late-stage clinical development for liver and cardiometabolic diseases. Key therapeutic areas like MASH, AUD, and ALD are attracting significant investment and research from numerous companies, including both large pharmaceutical firms and smaller biotech players. The industry is characterized by long development cycles, high R&D costs, and stringent regulatory hurdles.
Top Tags
corporate-governance (5) · financials (4) · Biotechnology (3) · 10-Q (3) · institutional-ownership (3) · filing (2) · 8-K (2) · Cash Burn (2) · governance (2) · executive-compensation (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Form Type | S-3MEF | Indicates a post-effective amendment to add securities to a prior S-3 registration |
| 8-K iXBRL Size | 99496 | Size of the main 8-K filing document in bytes. |
| Complete Submission Text File Size | 227830 | Size of the complete submission text file in bytes. |
| Net Loss (9 months) | $60.735M | Decreased from $71.879 million in 2024, showing improved financial performance. |
| Research and Development Expenses (Q3) | $14.960M | Decreased from $19.803 million in Q3 2024, indicating reduced burn rate. |
| Cash, Cash Equivalents and Restricted Cash | $61.278M | Increased from $36.968 million at December 31, 2024, strengthening liquidity. |
| Proceeds from At-the-Market Offerings | $112.088M | Significant capital raised through equity issuance during the nine months ended September 30, 2025. |
| Proceeds from Term Loan | $15.000M | New debt financing secured during the nine months ended September 30, 2025. |
| Total Assets | $218.447M | Increased from $139.306 million at December 31, 2024, reflecting growth in financial resources. |
| Term Loan, Noncurrent | $14.445M | New long-term debt obligation as of September 30, 2025. |
| Shares Issued and Outstanding | 95,598,665 | Increased from 72,352,701 shares at December 31, 2024, indicating significant shareholder dilution. |
| Net Loss Per Share (Q3) | $0.21 | Improved from $0.32 in Q3 2024, reflecting a smaller loss per share. |
| Net Loss Per Share (9 months) | $0.74 | Improved from $1.01 in the prior year, indicating a reduced loss per share over the longer period. |
| Fiscal Year | 2024 | The period covered by the executive compensation and equity award disclosures. |
| Report Date | 20250925 | The period for which the DEF 14A filing is made. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Altimmune, Inc. (ALT)?
Altimmune, Inc. has 37 recent SEC filings from Jan 2024 to Apr 2026, including 12 8-K, 11 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ALT filings?
Across 37 filings, the sentiment breakdown is: 1 bearish, 35 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Altimmune, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Altimmune, Inc. (ALT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Altimmune, Inc.?
Key financial highlights from Altimmune, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ALT?
The investment thesis for ALT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Altimmune, Inc.?
Key executives identified across Altimmune, Inc.'s filings include Dr. David J. Ebersole, Mr. Scott M. Canute, Dr. Vipin K. Garg, Mr. Michael J. McVoy, Dr. Scott Harris and 2 others.
What are the main risk factors for Altimmune, Inc. stock?
Of ALT's 24 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Altimmune, Inc.?
Forward guidance and predictions for Altimmune, Inc. are extracted from SEC filings as they are enriched.